| Literature DB >> 35441879 |
Nico C Grossmann1, Victor M Schuettfort2, Christian D Fankhauser1, Benedikt Kranzbühler1, Jeannine Betschart1, Anton S Becker3, Thomas Hermanns4, Etienne X Keller1.
Abstract
In patients with symptomatic ureterolithiasis, immediate treatment of concomitant urinary tract infection (UTI) may prevent sepsis. However, urine cultures require at least 24 h to confirm or exclude UTI, and therefore, clinical variables may help to identify patients who require immediate empirical broad-spectrum antibiotics and surgical intervention. Therefore, we divided a consecutive cohort of 705 patients diagnosed with symptomatic ureterolithiasis at a single institution between 2011 and 2017 into a training (80%) and a testing cohort (20%). A machine-learning-based variable selection approach was used for the fitting of a multivariable prognostic logistic regression model. The discriminatory ability of the model was quantified by the area under the curve (AUC) of receiver-operating curves (ROC). After validation and calibration of the model, a nomogram was created, and decision curve analysis (DCA) was used to evaluate the clinical net-benefit. UTI was observed in 40 patients (6%). LASSO regression selected the variables elevated serum CRP, positive nitrite, and positive leukocyte esterase for fitting of the model with the highest discriminatory ability. In the testing cohort, model performance evaluation for prediction of UTI showed an AUC of 82 (95% CI 71.5-95.7%). Model calibration plots showed excellent calibration. DCA showed a clinically meaningful net-benefit between a threshold probability of 0 and 80% for the novel model, which was superior to the net-benefit provided by either one of its singular components. In conclusion, we developed and internally validated a logistic regression model and a corresponding highly accurate nomogram for prediction of concomitant positive midstream urine culture in patients presenting with symptomatic ureterolithiasis.Entities:
Keywords: Infected stone; Nomogram; Prediction model; Predictors; Ureter calculus; Urine culture
Mesh:
Year: 2022 PMID: 35441879 PMCID: PMC9110449 DOI: 10.1007/s00240-022-01323-4
Source DB: PubMed Journal: Urolithiasis ISSN: 2194-7228 Impact factor: 3.436
Association of urinary tract infection with patient characteristics, clinical/radiological findings, treatment and outcome in 705 patients and stratification by training/testing cohort
| Variable | Overall | Urinary tract infection | Test/train cohort | ||||
|---|---|---|---|---|---|---|---|
| No UTI, | UTI, | Training cohort (80%), | Testing cohort (20%), | ||||
| Age | 45 (35, 56) | 45 (35, 55) | 56 (40, 68) | < 0.001 | 45 (35, 56) | 46 (37, 54) | 0.7 |
| Sex | 0.13 | 0.7 | |||||
| Female | 137 (19%) | 125 (19%) | 12 (30%) | 112 (20%) | 25 (18%) | ||
| Male | 568 (81%) | 540 (81%) | 28 (70%) | 452 (80%) | 116 (82%) | ||
| Pregnancy | 139 (20%) | 127 (19%) | 12 (30%) | 0.14 | 114 (20%) | 25 (18%) | 0.6 |
| Immuno-suppression | 59 (8.4%) | 54 (8.1%) | 5 (12%) | 0.4 | 48 (8.5%) | 11 (7.8%) | > 0.9 |
| Autoimmune/rheumatoid disease | 16 (2.3%) | 16 (2.4%) | 0 (0%) | > 0.9 | 11 (2.0%) | 5 (3.5%) | 0.3 |
| Diabetes | 41 (5.8%) | 36 (5.4%) | 5 (12%) | 0.075 | 36 (6.4%) | 5 (3.5%) | 0.3 |
| Nausea | 238 (34%) | 226 (34%) | 12 (30%) | 0.7 | 190 (34%) | 48 (34%) | > 0.9 |
| Vomitus | 178 (25%) | 171 (26%) | 7 (18%) | 0.3 | 134 (24%) | 44 (31%) | 0.087 |
| Gross hematuria | 111 (16%) | 105 (16%) | 6 (15%) | > 0.9 | 92 (16%) | 19 (13%) | 0.5 |
| Dysuria | 89 (13%) | 78 (12%) | 11 (28%) | 0.008 | 71 (13%) | 18 (13%) | > 0.9 |
| Pollakisuria | 62 (8.8%) | 56 (8.4%) | 6 (15%) | 0.2 | 48 (8.5%) | 14 (9.9%) | 0.7 |
| Costovertebral punch sign | 393 (56%) | 370 (56%) | 23 (57%) | > 0.9 | 312 (55%) | 81 (57%) | 0.7 |
| Flank back pain | 610 (87%) | 577 (87%) | 33 (82%) | 0.6 | 485 (86%) | 125 (89%) | 0.5 |
| Abdominal pain | 299 (42%) | 284 (43%) | 15 (38%) | 0.6 | 244 (43%) | 55 (39%) | 0.4 |
| Inguinal testicular/labial pain | 245 (35%) | 234 (35%) | 11 (28%) | 0.4 | 195 (35%) | 50 (35%) | > 0.9 |
| Systolic blood pressure | 142 (130, 154) | 142 (130, 154) | 135 (124, 149) | 0.082 | 142 (129, 154) | 142 (131, 157) | 0.7 |
| Unknown | 116 | 113 | 3 | 96 | 20 | ||
| Diastolic blood pressure | 88 (77, 96) | 88 (78, 96) | 82 (71, 90) | 0.006 | 88 (77, 96) | 88 (80, 98) | 0.3 |
| Unknown | 116 | 113 | 3 | 96 | 20 | ||
| Pulse | 72 (64, 84) | 72 (64, 83) | 86 (64, 96) | 0.009 | 73 (64, 83) | 72 (64, 86) | 0.4 |
| Unknown | 114 | 111 | 3 | 95 | 19 | ||
| Temperature | 36.7 (36.4, 37.1) | 36.7 (36.4, 37.0) | 36.9 (36.4, 37.6) | 0.046 | 36.7 (36.4, 37.1) | 36.6 (36.4, 37.0) | 0.075 |
| Unknown | 138 | 136 | 2 | 112 | 26 | ||
| Grade of ectasia | 0.005 | 0.2 | |||||
| No ectasia | 106 (15%) | 103 (16%) | 3 (7.7%) | 80 (14%) | 26 (18%) | ||
| 1° ectasia | 383 (55%) | 366 (55%) | 17 (44%) | 317 (57%) | 66 (47%) | ||
| 2° ectasia | 177 (25%) | 165 (25%) | 12 (31%) | 136 (24%) | 41 (29%) | ||
| 3° ectasia | 36 (5.1%) | 29 (4.4%) | 7 (18%) | 28 (5.0%) | 8 (5.7%) | ||
| Fornix rupture | 28 (4.0%) | 26 (3.9%) | 2 (5.0%) | 0.7 | 20 (3.6%) | 8 (5.7%) | 0.4 |
| Perirenal stranding | 220 (31%) | 203 (31%) | 17 (42%) | 0.2 | 182 (32%) | 38 (27%) | 0.3 |
| Position of ureter stone | 0.4 | 0.004 | |||||
| Distal ureter | 428 (61%) | 407 (61%) | 21 (52%) | 325 (58%) | 103 (73%) | ||
| Middle ureter | 94 (13%) | 89 (13%) | 5 (12%) | 82 (15%) | 12 (8.5%) | ||
| Proximale ureter | 182 (26%) | 168 (25%) | 14 (35%) | 156 (28%) | 26 (18%) | ||
| Second ipsilateral stone | < 0.001 | 0.3 | |||||
| None | 392 (56%) | 382 (57%) | 10 (25%) | 310 (55%) | 82 (58%) | ||
| Nephrolithiasis | 37 (5.2%) | 32 (4.8%) | 5 (12%) | 28 (5.0%) | 9 (6.4%) | ||
| Ureterolithiasis | 274 (39%) | 249 (37%) | 25 (62%) | 225 (40%) | 49 (35%) | ||
| Size of biggest ureter stone (mm) | 5.00 (4.00, 6.00) | 5.00 (4.00, 6.00) | 6.00 (4.00, 8.00) | 0.005 | 5.00 (4.00, 6.00) | 5.00 (4.00, 6.00) | 0.6 |
| Empiric antibiotic treatment | 107 (15%) | 78 (12%) | 29 (72%) | < 0.001 | 87 (15%) | 20 (14%) | 0.8 |
| Out or inpatient treatment | < 0.001 | 0.4 | |||||
| In-patient | 289 (41%) | 255 (38%) | 34 (85%) | 226 (40%) | 63 (45%) | ||
| Out-patient | 416 (59%) | 410 (62%) | 6 (15%) | 338 (60%) | 78 (55%) | ||
| Duration inpatient stay days | 0.00 (0.00, 3.00) | 0.00 (0.00, 2.00) | 4.50 (2.75, 7.00) | < 0.001 | 0.00 (0.00, 3.00) | 0.00 (0.00, 3.00) | 0.4 |
| Subsequent surgical renal decompression | 208 (30%) | 178 (27%) | 30 (75%) | < 0.001 | 162 (29%) | 46 (33%) | 0.5 |
| Development of sepsis | 7 (1.0%) | 5 (0.8%) | 2 (5.0%) | 0.055 | 5 (0.9%) | 2 (1.4%) | 0.6 |
| Urinary tract infection | 40 (5.7%) | 30 (5.3%) | 10 (7.1%) | 0.5 | |||
Statistics presented: median (IQR); n (%). Statistical tests performed: Wilcoxon rank-sum test; Chi-square test of independence; Fisher's exact test
UTI urinary tract infection
Association of urinary tract infection with laboratory findings in 705 patients and stratification by training/testing cohort
| Variable | Overall | Urinary tract infection | Test/train cohort | ||||
|---|---|---|---|---|---|---|---|
| No UTI, | UTI, | Training cohort (80%), | Testing cohort (20%), | ||||
| Hemoglobin (range: male: 13.5–17.5 g/dL; female: 12.0–15.5 g/dL) | 0.10 | 0.002 | |||||
| Normal | 630 (95%) | 595 (95%) | 35 (88%) | 496 (94%) | 134 (99%) | ||
| Decreased | 33 (5.0%) | 28 (4.5%) | 5 (12%) | 32 (6.1%) | 1 (0.7%) | ||
| Elevated | 1 (0.2%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 1 (0.7%) | ||
| Unknown | 41 | 41 | 0 | 36 | 5 | ||
| Thrombocytes (range 150–450 × 109/ L) | 0.2 | 0.048 | |||||
| Normal | 636 (96%) | 599 (96%) | 37 (92%) | 504 (95%) | 132 (97%) | ||
| Decreased | 21 (3.2%) | 18 (2.9%) | 3 (7.5%) | 20 (3.8%) | 1 (0.7%) | ||
| Elevated | 7 (1.1%) | 7 (1.1%) | 0 (0%) | 4 (0.8%) | 3 (2.2%) | ||
| Unknown | 41 | 41 | 0 | 36 | 5 | ||
| Leukocytes (range 4.5–11.0 × 109/L) | 0.021 | 0.5 | |||||
| Normal | 378 (57%) | 361 (58%) | 17 (42%) | 300 (57%) | 78 (57%) | ||
| Decreased | 2 (0.3%) | 1 (0.2%) | 1 (2.5%) | 1 (0.2%) | 1 (0.7%) | ||
| Elevated | 284 (43%) | 262 (42%) | 22 (55%) | 227 (43%) | 57 (42%) | ||
| Unknown | 41 | 41 | 0 | 36 | 5 | ||
| Neutrophil granulocytes (range 2.0–7.5 × 109/L) | 0.040 | 0.5 | |||||
| Normal | 331 (59%) | 320 (60%) | 11 (37%) | 266 (60%) | 65 (55%) | ||
| Decreased | 4 (0.7%) | 4 (0.7%) | 0 (0%) | 4 (0.9%) | 0 (0%) | ||
| Elevated | 230 (41%) | 211 (39%) | 19 (63%) | 177 (40%) | 53 (45%) | ||
| Unknown | 140 | 130 | 10 | 117 | 23 | ||
| Lymphocytes (range 1.5–4.5 × 109/L) | 0.010 | > 0.9 | |||||
| Normal | 481 (85%) | 460 (86%) | 21 (70%) | 380 (85%) | 101 (86%) | ||
| Decreased | 54 (9.6%) | 46 (8.6%) | 8 (27%) | 43 (9.6%) | 11 (9.3%) | ||
| Elevated | 30 (5.3%) | 29 (5.4%) | 1 (3.3%) | 24 (5.4%) | 6 (5.1%) | ||
| Unknown | 140 | 130 | 10 | 117 | 23 | ||
| CRP levels elevated (> 5 mg/L) | 169 (25%) | 146 (23%) | 23 (57%) | < 0.001 | 130 (25%) | 39 (29%) | 0.3 |
| Unknown | 42 | 42 | 0 | 35 | 7 | ||
| Creatinine elevated (> 1.2 mg/dl) | 153 (23%) | 137 (22%) | 16 (40%) | 0.015 | 125 (24%) | 28 (21%) | 0.5 |
| Unknown | 43 | 43 | 0 | 38 | 5 | ||
| Leukocyte esterase | < 0.001 | 0.12 | |||||
| Negative | 562 (83%) | 550 (87%) | 12 (30%) | 451 (85%) | 111 (79%) | ||
| Positive (> 75 Leukocytes/µl) | 112 (17%) | 84 (13%) | 28 (70%) | 82 (15%) | 30 (21%) | ||
| Unknown | 31 | 31 | 0 | 31 | 0 | ||
| Erythrocytes (hemoglobin) | 0.065 | 0.4 | |||||
| Normal | 120 (18%) | 114 (18%) | 6 (15%) | 99 (19%) | 21 (15%) | ||
| Positive (> 1 mg/L) | 554 (79%) | 520 (78%) | 34 (85%) | 434 (77%) | 113 (80%) | ||
| Unknown | 31 | 31 | 0 | 31 | 0 | ||
| Nitrite | < 0.001 | > 0.9 | |||||
| Negative | 658 (98%) | 630 (99%) | 28 (70%) | 520 (98%) | 138 (98%) | ||
| Positive (> 0.1 mg/dL) | 15 (2.2%) | 3 (0.5%) | 12 (30%) | 12 (2.3%) | 3 (2.1%) | ||
| Unknown | 32 | 32 | 0 | 32 | 0 | ||
| pH value | 0.9 | 0.8 | |||||
| Unknown | 31 | 31 | 0 | 31 | 0 | ||
Statistics presented: n (%). Statistical tests performed: Wilcoxon rank-sum test; Chi-square test of independence; Fisher's exact test
UTI urinary tract infection, CRP C-reactive protein
Fig. 1Uni- and multivariable logistic regression model for prediction of positive midstream urine culture (left). The model was fitted using LASSO regression with tenfold cross-validation. Nomogram predicting risk of positive midstream urine culture based on the logistic regression model (n = 705, right). CRP C-reactive protein, OR Odds ratio, 95%CI 95% confidence interval
Fig. 2Receiver-operating characteristic curves and model performance evaluation for the prediction of positive midstream urine culture based on the logistic regression model (left: training cohort n = 564; middle: testing cohort n = 141, right: full cohort n = 705). AUC area under the curve, 95%CI 95% confidence interval
Fig. 3A Calibration plots of the logistic regression model predicting of positive midstream urine culture, 200-fold bootstrap corrected (left: training cohort n = 564; middle testing cohort, n = 141; right entire cohort, n = 705). B Decision curve analyses for the evaluation of the clinical net-benefit using the novel logistic regression model for prediction of positive midstream urine culture (n = 705). CRP C-reactive protein